What Sudo Biosciences does

Sudo Biosciences is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Carmel, Indiana, with additional operations in London, United Kingdom. The company designs and develops small-molecule medicines that selectively inhibit tyrosine kinase 2 (TYK2) through its regulatory pseudokinase (JH2) domain, an allosteric approach intended to deliver potent pathway blockade with minimized off-target activity compared to traditional JAK family inhibitors that target the catalytic JH1 domain. Its pipeline currently comprises three programs: SUDO-550, an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neuroinflammatory and neurodegenerative conditions (Phase 1 completed with a Phase 2 MS study planned for H1 2026); SUDO-286, a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic diseases (Phase 1); and a preclinical ophthalmic TYK2 program. The company is led by a management team with prior operating experience at Pfizer, Eli Lilly, Array Biopharma, GW Pharmaceuticals, Mitsubishi Tanabe, and Frazier Life Sciences.

The company's underlying technology platform centers on medicinal chemistry optimization of allosteric TYK2 JH2 binders, combined with translational biology capabilities that integrate human genetic evidence, proteomics, and disease-relevant biomarkers to support target selection and clinical development. Phase 1 results for SUDO-550 demonstrated >90% inhibition of TYK2-mediated signaling with equivalent free concentrations in plasma and cerebrospinal fluid, supporting once-daily oral dosing and CNS penetration — a profile that addresses a major limitation of existing MS therapies that do not adequately target the neurodegenerative component of disease. The topical SUDO-286 program is designed to achieve localized TYK2 inhibition in dermatologic indications with the aim of improving the safety profile relative to systemic JAK inhibitors.

Sudo Biosciences is pre-revenue and generates no commercial product sales. The business model is structured around advancing proprietary drug candidates through clinical development to regulatory approval, with future revenue intended to come from the commercialization of FDA-approved TYK2 inhibitor therapies via prescription drug distribution channels (specialty pharmacies, hospital systems, retail pharmacies). To date the company has financed operations through equity capital, raising $188 million in cumulative funding across a $37 million Series A (September 2022) and a $147 million Series B (December 2023 initial close plus January 2024 second close), with lead investors including Frazier Life Sciences, Velosity Capital, Enavate Sciences, and TPG.

Name

Sudo Biosciences

Legal name

Sudo Biosciences, Inc.

Website

https://sudobio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Sudo Biosciences is a clinical-stage biopharmaceutical company developing allosteric small-molecule TYK2 (tyrosine kinase 2) pseudokinase inhibitors for serious neurological and immunological conditions, including multiple sclerosis, neurodegenerative diseases, and psoriasis. The company is pre-revenue and financed through venture capital.

Ownership category

akta.pro rank

Headquarters

HQ city

Carmel

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical stage biopharmaceutical company. Revenue will be generated through the commercialization of FDA-approved TYK2 inhibitor therapies for autoimmune and neurological diseases upon successful completion of clinical trials and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation small molecule medicines that inhibit tyrosine kinase 2 (TYK2) through its pseudokinase (JH2) regulatory domain. Its lead candidate SUDO-550 is an oral, brain-penetrant allosteric TYK2 inhibitor for multiple sclerosis and other neurodegenerative diseases; SUDO-286 is a topical TYK2 inhibitor for psoriasis and immune-mediated dermatologic conditions; an ophthalmic TYK2 program is in preclinical development. The company designs and develops these precision TYK2 therapeutics for serious neurological and immunological conditions.

Product overview

Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 (tyrosine kinase 2) pseudokinase inhibitors. The company's pipeline consists of three distinct product candidates: SUDO-550 (a brain-penetrant oral inhibitor for multiple sclerosis and neurodegenerative diseases, currently in Phase 1), SUDO-286 (a topical inhibitor for dermatological conditions including psoriasis, in Phase 1), and an ophthalmic program (preclinical). The company leverages allosteric inhibition targeting the TYK2 pseudokinase (JH2) domain for selectivity over other JAK family members. Based in Carmel, IN and London, UK, Sudo is advancing these precision medicines for immune-mediated and neurological conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• SUDO-550 SUDO-550 is a potential first-in-class and best-in-class, oral, CNS-penetrant allosteric TYK2 (tyrosine kinase 2) pseudokinase inhibitor designed for once-daily dosing. It achieves potent and selective inhibition of TYK2-mediated signaling across both the central nervous system and peripheral immune systems, targeting the IL-12, IL-23, and Type I interferon pathways. It is being developed for multiple sclerosis and other neurodegenerative conditions with underlying neuroinflammation and is currently in Phase 1 with a planned Phase 2 in MS in H1 2026.
• SUDO-286 SUDO-286 is a highly potent, selective, and potential first- and best-in-class topical TYK2 pseudokinase inhibitor being developed for psoriasis and other immune-mediated dermatologic diseases. It is being evaluated in two Phase 1 clinical studies in healthy volunteers and patients.
• Ophthalmic TYK2 Inhibitor Program

Quantifiable outcome

• Phase 1 results demonstrated SUDO-550 was safe, well tolerated, and achieved >90% inhibition of TYK2-mediated signaling
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Roche: Markets Ocrevus and other MS therapies, setting the standard of care against which SUDO-550's Phase 2 MS readout will be benchmarked. Also relevant as a potential strategic acquirer of differentiated CNS candidates.
• Takeda Pharmaceutical: Licensed Nimbus's allosteric TYK2 program (NDI-034858 / zasocitinib) and is actively developing it in psoriasis and IBD. Direct competing oral TYK2 mechanism with deep CNS and autoimmune commercial reach.
• AbbVie: Markets Rinvoq (upadacitinib) and Skyrizi (risankizumab), major immunology franchises targeting overlapping IL-12/IL-23/JAK pathways. Sets the efficacy and commercial benchmark Sudo's candidates will need to beat in psoriasis and autoimmune indications.
• Pfizer: Markets Litfulo (ritlecitinib) and Cibinqo (abrocitinib) and historically led TYK2/JAK clinical development. Many Sudo executives (Mills, McMurray, Eccles) came from Pfizer, making it both a talent feeder and a competitive reference point.
• Biogen: Major neuroscience-focused biopharma with the leading MS franchise (Tysabri, Tecfidera, Vumerity). Comparable as a partner or acquirer of differentiated CNS candidates and as the benchmark commercial entity for MS launches.
• Bristol Myers Squibb: Markets Sotyktu (deucravacitinib), the first FDA-approved allosteric TYK2 inhibitor for psoriasis, and is expanding into additional immunology indications. It is the most important direct competitor to Sudo's oral and topical TYK2 programs.

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation immunology drugs (e.g., KT-474). Comparable as a well-funded, private/platform-based autoimmune biotech pursuing differentiated mechanisms against validated targets.
• Dice Therapeutics: Was a private DEL-based oral IL-17/TYK2-adjacent immunology company acquired by Eli Lilly for ~$2.4B in 2023. Highly comparable as an autoimmune-focused platform that reached an exit while still clinical-stage.
• Nimbus Therapeutics: Private, computationally driven drug discovery company with a TYK2 allosteric inhibitor program (NDI-034858 / takeverant) licensed to Takeda for autoimmune disease. Direct mechanistic parallel to Sudo's platform.
• Alumis: Clinical-stage immunology company developing allosteric TYK2 inhibitors (e.g., ESK-001) for autoimmune disease, with significant funding from institutional investors. Closely comparable as a private TYK2-focused peer pursuing the same pseudokinase mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sudo-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sudo Biosciences